GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Avarept® | compound 1 [WO2024071349] | SJP-0132 | SJP0132
motugivatrep is an approved drug
Compound class:
Synthetic organic
Comment: Motugivatrep (SJP-0132) is a selective transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist [3]. It was designed to ameliorate the signs and symptoms dry eye disease.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Motugivatrep (SJP-0132) was progressed as a clinical candidate in participants with with dry eye-related symptoms. First approval was granted by Japan's PMDA in December 2025. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04139122 | Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease | Phase 1/Phase 2 Interventional | Senju Pharmaceutical Co., Ltd. | 1-2 | |